<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5090657 Figure_1-B</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Beta-hydroxybutyrate (ketone body) concentrations, plasma.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_1-C</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Creatine kinase (CK) concentrations, plasma.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_1-D</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Myoglobin concentrations, plasma. Dashed line: upper limit of control range. The individual patients are shown separately, and controls as mean with standard deviation (n=10). Arrow: mAD endpoint in PEO patients; lines under graphs: duration of mAD.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_1-E-K</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 1-E-K</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E-K</infon>
    <passage>
      <offset>0</offset>
      <text>E-G. PEO patient (P1) muscle before diet: E. Ultrathin section of abnormal muscle fiber (arrowhead) with subsarcolemmal accumulations of mitochondria. Scale bar 50 &#181;m F. Electron micrograph of subsarcolemmal accumulation of abnormal mitochondria (same cell as in E). G. Enlargement of the area marked in F; mitochondria with paracrystalline "parking lot" inclusions (arrow) and concentric cristae (asterisk). Scale bar 1&#181;m H-J. PEO patient (P1) muscle after mAD (H-J): H. Ultrathin section, lytic muscle fiber with centrally located organellar debris (arrow). Scale bar 50 &#181;m I. Electron micrograph of a degrading muscle fiber with an invaded macrophage (arrow) (same cell as in H). J. Enlargement of the fiber in I: paracrystalline inclusions within mitochondria (asterisk). Scale bar 1&#181;m K. Quantification of necrotic or apoptotic cells in PEO muscle from ultrathin sections. n.a., not available.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_2-A-B</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 2-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A-B. Cleaved caspase-3 positive muscle fibers (*). A. PEO patient (P3) on normal diet (inset: caspase staining in healthy control individual) B. PEO patient (P3) after modified Atkins diet. Arrowhead: caspase negative necrotic fiber.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_2-C</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 2-C</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Western blot analysis of autophagy receptor p62 and pax7 marking muscle satellite cell activation; left, blot; right, signal quantification in each patient.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_2-D-G</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 2-D-G</infon>
    <infon key="sourcedata_figure_dir">Figure_2-D-G</infon>
    <passage>
      <offset>0</offset>
      <text>D - E. Immunohistochemistry analysis of p62 and mitochondrial mass marker, consecutive sections. Asterisks indicate p62-positive fibers and corresponding affected ragged-red fibers. F - G. p62 and mitochondrial mass after mAD; consecutive sections. Arrowheads indicate fibers that show p62 positivity but have normal mitochondrial mass.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_2-H-I</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 2-H-I</infon>
    <infon key="sourcedata_figure_dir">Figure_2-H-I</infon>
    <passage>
      <offset>0</offset>
      <text>H. p62 and LC3 positive ragged-red fibers (*) in PEO patient (P2), normal diet. I. Muscle fibers showing granular LC3-positivity, PEO patient (P1), after mAD. Immunohistochemistry on frozen sections; bars: 50 &#181;m, except for H, 100 &#181;m.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_3-A-B-C</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 3-A-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>A-C. Muscle strength and performance of PEO patients (P1-P4) on normal diet (ND) and after modified Atkins diet (mAD) (one and six months and 2.5 years after initiation of diet).</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_3-D-G</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 3-D-G</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D-G</infon>
    <passage>
      <offset>0</offset>
      <text>D-G. Spiroergometry results from PEO patients and control subjects on normal diet (ND), as well as one month and six months after mAD initiation. PEO patients had higher serumlactate levels, and attenuated respiratory response to exercise. These effects were further enhanced after mAD and remained after 6 months of the study. mAD increased patients' serumammonium (NH4+) levels. Data presented as mean and SD.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_5-A-B</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 5-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A. PEO patients, relative amino acid levels on normal diet (PEO), immediately after finishing mAD (PEO_mAD), and one month after mAD. B. Control subjects, relative amino acid levels on normal diet (Control) and immediately after finishing mAD (Control_mAD).</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_5-C</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Relative values of plasma metabolites in creatine pathway, compared to controls on ND. Right: illustration of major metabolites and pathway of creatine synthesis.</text>
    </passage>
  </document>
  <document>
    <id>5090657 Figure_5-D</id>
    <infon key="sourcedata_document">2263</infon>
    <infon key="doi">10.15252/emmm.201606592</infon>
    <infon key="pmc_id">5090657</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Relative values of plasma purine and pyrimidine degradation pathway intermediates, compared to controls on ND. Right: illustration of major metabolites and synthesis of pyrimidine and purines.</text>
    </passage>
  </document>
</collection>
